<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Basiliximab, a chimeric interleukin-2 receptor (IL-2-R) <z:chebi fb="68" ids="48706">antagonist</z:chebi>, was evaluated in 17 patients with steroid-refractory <z:hpo ids='HP_0011009'>acute</z:hpo> <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> (GVHD) after allogeneic stem cell transplantation (SCT) </plain></SENT>
<SENT sid="1" pm="."><plain>Patients were transplanted from a related (n = 6) or unrelated (n = 11) HLA-identical donor because of <z:hpo ids='HP_0006721'>acute lymphoblastic leukemia</z:hpo> (n = 4), <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (n = 3), <z:hpo ids='HP_0011010'>chronic</z:hpo> myeloid <z:hpo ids='HP_0001909'>leukemia</z:hpo> (n = 7), <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> (n = 1), non-Hodgkin's <z:hpo ids='HP_0002665'>lymphoma</z:hpo> (n = 1), and <z:hpo ids='HP_0006775'>multiple myeloma</z:hpo> (n = 1) </plain></SENT>
<SENT sid="2" pm="."><plain>Basiliximab was given at a dose of 2 x 20 mg on 2 consecutive days after steroid-refractory <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD had developed </plain></SENT>
<SENT sid="3" pm="."><plain>Basiliximab was repeated on day 8 in cases of persistent GVHD </plain></SENT>
<SENT sid="4" pm="."><plain>A median of four basiliximab infusions (range 1-12) were given to these patients </plain></SENT>
<SENT sid="5" pm="."><plain>None had infusion-associated or cytokine-related side-effects after basiliximab </plain></SENT>
<SENT sid="6" pm="."><plain>Twelve of 17 patients (71%) responded to basiliximab, 9/17 (53%) had a complete response (CR) of <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD and 3/17 (18%) had a partial response (PR) </plain></SENT>
<SENT sid="7" pm="."><plain>Five of 17 patients (29%) did not respond </plain></SENT>
<SENT sid="8" pm="."><plain><z:hpo ids='HP_0011010'>Chronic</z:hpo> GVHD developed in 8/13 evaluable patients and only 2/8 had responded to basiliximab before </plain></SENT>
<SENT sid="9" pm="."><plain>Five of 13 evaluable patients have no signs of <z:hpo ids='HP_0011010'>chronic</z:hpo> GVHD and <z:hpo ids='HP_0000001'>all</z:hpo> five had a CR or PR after basiliximab </plain></SENT>
<SENT sid="10" pm="."><plain>This is the first report on the safety of basiliximab in patients with steroid-refractory <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD </plain></SENT>
<SENT sid="11" pm="."><plain>Our data suggest that basiliximab is effective in a substantial proportion of these patients </plain></SENT>
</text></document>